Hikma invests $267 million in Ohio as Cingulate receives CRL for ADHD candidate
Hikma Pharmaceuticals, a generic drugmaker, announced a $267 million investment to expand its manufacturing footprint in Ohio. The plan includes $216 million to upgrade its existing Columbus plant and an additional $51 million to add new production capacity.
The expansion is expected to create jobs and boost the supply of generic medicines for the U.S. market, reinforcing Hikma's presence in the region.
In a separate development, Cingulate Pharmaceuticals received a complete response letter from the FDA regarding its experimental ADHD drug, indicating that the agency requires further data before considering approval.
The CRL represents a regulatory setback for Cingulate, delaying any potential market launch of the candidate.
Together, the news underscores ongoing growth in generic drug manufacturing while highlighting the regulatory hurdles that novel therapies continue to face.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Hikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that